One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Atea Pharmaceuticals, Inc.
AVIR · NMS · Healthcare · Biotechnology
Current price
$4.98
52-week range
$2.87 - $6.45
Market cap
$399.42M
Balance sheet
Healthy
-11.05x Concerning
Net cash $219.04M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals is developing new pill-based medicines to fight serious viral infections, like hepatitis C. Their main money comes from getting investments to fund their research and development, since they haven't sold any approved drugs yet. This is important because the success of their drug trials will determine if they can eventually bring these treatments to patients and make money.
How the company got here
Atea Pharmaceuticals was founded in 2012 with the goal of creating new medicines for serious viral diseases. The company has focused on developing oral antiviral drugs, which are pills patients can take at home, rather than needing injections or hospital visits. A key moment for Atea was advancing its lead drug candidates into clinical trials, showing promising early results in treating conditions like Hepatitis C. This progress has been crucial in attracting partnerships and funding to continue its research and development efforts.
What it actually does
Atea Pharmaceuticals is a biopharmaceutical company that works on discovering and developing new medicines. Specifically, they focus on creating antiviral drugs that can be taken orally (as pills) to treat serious viral infections. Their work involves complex science to design molecules that can stop viruses from multiplying in the body. The ultimate aim is to provide effective treatments for patients suffering from challenging viral diseases, improving their health outcomes and quality of life.
Hepatic C Virus (HCV) Therapeutics
This is Atea's main area of focus, aiming to treat Hepatitis C, a liver infection caused by a virus. Their lead treatment is a combination of two drugs, bemnifosbuvir and ruzasvir, which are designed to stop the Hepatitis C virus from replicating. These drugs are currently in Phase 3 clinical trials, which are the final stage of testing before seeking approval from regulatory bodies. Success in this area could provide a new, convenient oral treatment option for millions of people worldwide affected by Hepatitis C.
Hepatitis E Virus (HEV) Therapeutics
Atea is also developing a treatment for Hepatitis E, another viral infection that affects the liver. Their drug candidate for this condition is called AT-587, and it is currently in Phase 1 clinical trials. Phase 1 trials are the first time a drug is tested in humans to assess its safety and determine the right dosage. This represents an expansion of Atea's efforts to tackle different types of viral infections with their oral antiviral technology.
Proprietary Nucleoside and Nucleotide Platform
Underpinning Atea's drug development is a specialized technology platform focused on nucleosides and nucleotides. These are building blocks used in creating antiviral drugs. This platform allows the company to design and develop new drug candidates for various virology (the study of viruses) and medicinal chemistry (the science of designing drugs) applications. It's the scientific engine that enables Atea to create its potential new medicines for different viral diseases.
What management is betting on now
Atea's management is primarily focused on successfully completing the ongoing clinical trials for its Hepatitis C and Hepatitis E drug candidates. The company is also leveraging its core technology platform to potentially discover and develop treatments for other serious viral infections. A key strategic priority is to advance these promising drug candidates through the rigorous testing phases required for regulatory approval. This strategy aims to bring new, effective oral antiviral therapies to patients and establish Atea as a leader in the field of virology.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
Revenue
—
Net income
$-32.93M
Diluted EPS
-0.41
Operating cash flow
$-37.08M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-45.44M
Diluted EPS
-0.57
Operating cash flow
$-46.39M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-44.87M
Diluted EPS
-0.57
Operating cash flow
$-28.22M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-42.05M
Diluted EPS
-0.53
Operating cash flow
$-40.38M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-37.16M
Diluted EPS
-0.44
Operating cash flow
$-32.87M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-34.27M
Diluted EPS
-0.40
Operating cash flow
$-30.56M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-33.54M
Diluted EPS
-0.40
Operating cash flow
$-30.40M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-31.15M
Diluted EPS
-0.37
Operating cash flow
$-23.04M
Free cash flow
—
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $4.98
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $219.0M - more cash than debt. Interest coverage -11.0x.
Net debt
$-219.04M
Interest coverage
-11.05x
Atea Pharmaceuticals, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 5 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
AVIR
BASELINE
Atea Pharmaceuticals, Inc.
Total debt $424.00K Interest coverage -11.05x This is the baseline the peer rows are being compared against.
Total debt $22.93M Interest coverage -8,473.33x Neither company has much profit cushion over interest right now.
Total debt $33.00M Interest coverage -347.29x Neither company has much profit cushion over interest right now.
Total debt $171.60M Interest coverage -69.05x Neither company has much profit cushion over interest right now.
Total debt $0.00 Interest coverage -11.88x Neither company has much profit cushion over interest right now.
Total debt $15.51M Interest coverage -16.10x Neither company has much profit cushion over interest right now.
What you should know
The case for and against AVIR
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -58.1% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-3.36x
P/B
1.96x
P/S
—
EV/EBITDA
-0.99x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-58.1%
ROA
-36.7%
Health
Liquidity and balance-sheet strength
Debt / equity
0.00x
Current ratio
8.13x
Quick ratio
7.80x
Total debt
$424.00K
Total cash
$219.46M
Growth
How the business has been compounding
Revenue TTM
$351.37M
Revenue 5Y CAGR
168.8%
EPS TTM
-2.06
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-152.07M
Free CF TTM
$-132.03M
FCF margin
-37.6%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—